Your browser is no longer supported. Please, upgrade your browser.
Settings
GTH [NASD]
Genetron Holdings Limited
Index- P/E- EPS (ttm)-15.61 Insider Own10.83% Shs Outstand29.48M Perf Week-5.50%
Market Cap1.60B Forward P/E- EPS next Y-0.38 Insider Trans0.00% Shs Float3.20M Perf Month-13.58%
Income-468.50M PEG- EPS next Q-0.18 Inst Own21.40% Short Float8.59% Perf Quarter15.64%
Sales64.80M P/S24.71 EPS this Y-32.40% Inst Trans3.86% Short Ratio0.67 Perf Half Y74.72%
Book/sh9.51 P/B2.11 EPS next Y36.70% ROA- Target Price26.22 Perf Year-
Cash/sh3.58 P/C5.61 EPS next 5Y- ROE- 52W Range9.03 - 31.54 Perf YTD43.64%
Dividend- P/FCF- EPS past 5Y- ROI-77.60% 52W High-36.24% Beta-
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin61.30% 52W Low122.70% ATR2.33
Employees663 Current Ratio5.70 Sales Q/Q-49.20% Oper. Margin- RSI (14)44.71 Volatility15.87% 10.43%
OptionableNo Debt/Eq0.06 EPS Q/Q93.00% Profit Margin- Rel Volume0.39 Prev Close20.55
ShortableYes LT Debt/Eq0.02 EarningsMar 25 BMO Payout- Avg Volume412.49K Price20.11
Recom1.50 SMA20-6.30% SMA50-16.16% SMA20025.92% Volume162,099 Change-2.14%
Jul-14-20Initiated Canaccord Genuity Buy $19
Jul-14-20Initiated BTIG Research Buy $20
Apr-13-21 01:31AM  
Apr-01-21 06:00PM  
06:39AM  
Mar-27-21 04:10AM  
Mar-25-21 06:47AM  
06:30AM  
Mar-24-21 05:00PM  
Mar-17-21 04:30PM  
Mar-15-21 06:24AM  
Mar-04-21 05:00PM  
Feb-09-21 07:00AM  
Jan-27-21 05:00AM  
Jan-13-21 06:30AM  
Jan-07-21 09:32AM  
08:20AM  
Jan-06-21 04:40AM  
Dec-20-20 03:04AM  
Dec-11-20 10:38PM  
Nov-27-20 08:00AM  
Nov-20-20 06:00AM  
Nov-19-20 09:53AM  
Nov-12-20 05:30AM  
Nov-09-20 06:30AM  
06:30AM  
Oct-29-20 08:00AM  
Oct-26-20 08:00AM  
Oct-22-20 06:00AM  
Sep-30-20 08:11AM  
Sep-25-20 06:00AM  
Sep-18-20 06:00AM  
Sep-08-20 04:15PM  
Aug-29-20 10:32AM  
Aug-06-20 06:30AM  
Jul-29-20 04:39PM  
Jul-27-20 04:30PM  
Jun-30-20 08:55AM  
Jun-19-20 08:45AM  
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of liver cancer. It also provides in-vitro diagnostics products, including 8-gene Lung Cancer Assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1/TERT gene assays for glioma; GENETRON S5, a semiconductor sequencer used in the field of gene detection; and Genetron S2000 that enables gene panel sequencing. In addition, the company develops ctDNA Lung Cancer assay for mutations in the epidermal growth factor receptor gene. It also offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a partnership agreement with dMed Biopharmaceutical for new drug research and development in the field of oncology. The company was founded in 2015 and is headquartered in Beijing, the People's Republic of China.